Abstract

Annexin A1 (AnxA1) is a protein with potent anti-inflammatory actions and an interesting target that has been poorly explored in skin inflammation. This work evaluated the lack of endogenous AnxA1 in the progression of ovalbumin (OVA)-induced atopic dermatitis (AD)-like skin lesions. OVA/Alum-immunized C57BL/6 male wild-type (WT) and AnxA1 null (AnxA1-/-) mice were challenged with drops containing OVA on days 11, 14–18 and 21–24. The AnxA1-/- AD group exhibited skin with intense erythema, erosion and dryness associated with increased skin thickness compared to the AD WT group. The lack of endogenous AnxA1 also increased IgE relative to WT animals, demonstrating exacerbation of the allergic response. Histological analysis revealed intense eosinophilia and mast-cell activation in AD animals, especially in AnxA1-/-. Both AD groups increased skin interleukin (IL)-13 levels, while IL-17A was upregulated in AnxA1-/- lymph nodes and mast cells. High levels of phosphorylated ERK were detected in keratinocytes from AD groups. However, phospho-ERK levels were higher in the AnxA1-/- when compared to the respective control groups. Our results suggest AnxA1 as an important therapeutic target for inflammatory skin diseases.

Highlights

  • Atopic dermatitis (AD), known as atopic eczema, is the most common chronic inflammation of skin is characterized by itchy, red, wet and cracked skin [1,2]

  • AD pathogenesis is attributed to imbalances in the adaptive immune system, including dysfunction of T helper (Th) lymphocytes and increased production of IgE [1,2,3,4]

  • Th17 lymphocytes predominate in patients with AD, but Th1 cells contribute to its pathogenesis

Read more

Summary

Introduction

Atopic dermatitis (AD), known as atopic eczema, is the most common chronic inflammation of skin is characterized by itchy, red, wet and cracked skin [1,2]. AD pathogenesis is attributed to imbalances in the adaptive immune system, including dysfunction of T helper (Th) lymphocytes and increased production of IgE [1,2,3,4]. Cytokines and chemokines, such as interleukin IL-4, IL-5, IL-13, eotaxins, chemokines CCL17, CCL18 and CCL22, produced by. Th2 and Th17 cells (IL-4/IL-13 and IL-17/IL-22, respectively) produce cytokines that inhibit terminal differentiation of epidermis and contribute to the rupture of the epithelial barrier in AD patients [1,2,4]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call